Thiazolidinedione use and bone loss in older diabetic adults

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 9, 2006, Pages 3349-3354

  Schwartz, Ann V ^a   Sellmeyer, Deborah E ^a   Vittinghoff, Eric ^a   Palermo, Lisa ^a   Lecka Czernik, Beata ^b   Feingold, Kenneth R ^a   Strotmeyer, Elsa S ^c   Resnick, Helaine E ^d   Carbone, Laura ^e   Beamer, Brock A ^f   Seok, Won Park ^c,g   Lane, Nancy E ^h   Harris, Tamara B ⁱ   Cummings, Steven R ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d MEDSTAR RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CHA University   (South Korea)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NATIONAL INSTITUTE ON AGING   (United States)

^j CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

AGED; ARTICLE; BODY COMPOSITION; BONE DENSITY; BONE METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; GLUCOSE TOLERANCE TEST; HUMAN; HYPOGLYCEMIA; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOLYSIS; PRIORITY JOURNAL; SELF REPORT; SIDE EFFECT; WEIGHT REDUCTION;

EID: 33748748473     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2226     Document Type: Article

References (30)

1. Yki-Jarvinen H 2004 Thiazolidinediones. N Engl J Med 351:1106-1118
2. Einhorn D, Aroda VR, Henry RR 2004 Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol Metab Clin North Am 33:595- 616, vii-viii
3. Wysowski DK, Armstrong G, Governale L 2003 Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care 26:1852-1855
4. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B 2004 Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406
5. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC 2004 Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183:203-216
6. Sottile V, Seuwen K, Kneissel M 2004 Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARγ agonist BRL49653 (rosiglitazone). Calcif Tissue Int 75:329-337
7. Tornvig L, Mosekilde LI, Justesen J, Falk E, Kassem M 2001 Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int 69:46-50
8. Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T 2003 Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab 21:166-171
9. Okazaki R, Miura M, Toriumi M, Taguchi M, Hirota Y, Fukumoto S, Fujita T, Tanaka K, Takeuchi A 1999 Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 46:795-801
10. Rubin GL, Zhao Y, Kalus AM, Simpson ER 2000 Peroxisome proliferator-activated receptor γ ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 60:1604-1608
11. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Zmuda JM, Bauer DC, Tylavsky FA, de Rekeneire N, Harris TB, Newman AB 2004 Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: the Health, Aging, and Body Composition Study. J Bone Miner Res 19:1084-1091
12. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P 1994 Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 10:405-411
13. Baran D, Leahey D, von Stetten E 1995 Clinical evaluation of a fourth generation fanbeam DXA system. J Bone Miner Res 10:S374 (Abstract)
14. Fuerst T, Gluer CC, Genant H 1995 Performance evaluation of a new bone densitometer: Hologic QDR-4500. J Bone Miner Res 10:S370 (Abstract)
15. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G 2003 National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137-147
16. McCulloch C, Searle S 2001 Generalized, linear, and mixed models. New York: Wiley
17. Dawson-Hughes B, Dallal GE 1990 Effect of radiographic abnormalities on rate of bone loss from the spine. Calcif Tissue Int 46:280-281
18. Greenspan SL, Maitland LA, Myers ER, Krasnow MB, Kido TH 1994 Femoral bone loss progresses with age: a longitudinal study in women over age 65. J Bone Miner Res 9:1959-1965
19. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Black DM, Cummings SR 2001 Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32-38
20. de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA 2005 Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16:1713-1720
21. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, de Rekeneire N, Harris TB, Newman AB 2005 Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 165:1612-1617
22. Spaine LA, Bollen SR 1996 'The bigger they come': the relationship between body mass index and severity of ankle fractures. Injury 27:687-689
23. Sornay-Rendu E, Munoz F, Duboeuf F, Delmas PD 2005 The rate of forearm bone loss is associated with an increased risk of fracture independently of bone mass in postmenopausal women. The OFELY study. J Bone Miner Res 20:1929-1935
24. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN 2001 Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86:1626-1632
25. Arlt W, Auchus RJ, Miller WL 2001 Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3β-hydroxysteroid dehydrogenase. J Biol Chem 276:16767-16771
26. Vierhapper H, Nowotny P, Waldhausl W 2003 Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone. Metabolism 52:230-232
27. Patel SM, Szapary P, Ratcliffe SJ, Wolfe ML, Cappola AR, The effect of pioglitazone on insulin sensitivity and androgen levels in nondiabetic patients with the metabolic syndrome: a double-blind, randomized, placebo-controlled dose escalation trial. Program of the 87th Annual Meeting of The Endocrine Society, San Diego, CA, 2005, p 265 (Abstract P1-393)
28. Tylavsky FA, Lohman TG, Dockrell M, Lang T, Schoeller DA, Wan JY, Fuerst T, Cauley JA, Nevitt M, Harris TB 2003 Comparison of the effectiveness of 2 dual-energy X-ray absorptiometers with that of total body water and computed tomography in assessing changes in body composition during weight change. Am J Clin Nutr 77:356-363
29. Chappard D, Moquereau M, Mercier P, Gallois Y, Legrand E, Basle MF, Audran M 2004 Ex vivo bone mineral density of the wrist: influence of medullar fat. Bone 34:1023-1028
30. Melton 3rd LJ, Looker AC, Shepherd JA, O'Connor MK, Achenbach SJ, Riggs BL, Khosla S 2005 Osteoporosis assessment by whole body region vs. site-specific DXA. Osteoporos Int 16:1558-1564